These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

24 related articles for article (PubMed ID: 39140597)

  • 1. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.
    Shapiro J; van Hagen P; Lingsma HF; Wijnhoven BP; Biermann K; ten Kate FJ; Steyerberg EW; van der Gaast A; van Lanschot JJ;
    Ann Surg; 2014 Nov; 260(5):807-13; discussion 813-4. PubMed ID: 25379852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial.
    Nilsson K; Klevebro F; Sunde B; Rouvelas I; Lindblad M; Szabo E; Halldestam I; Smedh U; Wallner B; Johansson J; Johnsen G; Aahlin EK; Johannessen HO; Alexandersson von Döbeln G; Hjortland GO; Wang N; Shang Y; Borg D; Quaas A; Bartella I; Bruns C; Schröder W; Nilsson M
    Ann Oncol; 2023 Nov; 34(11):1015-1024. PubMed ID: 37657554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
    Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
    Nilsson K; Klevebro F; Rouvelas I; Lindblad M; Szabo E; Halldestam I; Smedh U; Wallner B; Johansson J; Johnsen G; Aahlin EK; Johannessen HO; Hjortland GO; Bartella I; Schröder W; Bruns C; Nilsson M
    Ann Surg; 2020 Nov; 272(5):684-689. PubMed ID: 32833767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
    Hong ZN; Huang Z; Weng K; Lin J; Kang M
    Front Immunol; 2022; 13():1036396. PubMed ID: 36311738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Meta-analysis of Total Neoadjuvant Therapies Combining Chemoradiotherapy with Induction or Consolidated Chemotherapy for Locally Advanced Rectal Cancer.
    Nov P; Du K; Huang Z; Li Y; Gong M; Liu X; Li C; Li L; Wang D; Zhang Y; Wang C; Li J
    J Gastrointest Cancer; 2023 Sep; 54(3):693-702. PubMed ID: 36243897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Biermann K; van der Gaast A; Spaander MCW; Valkema R; van Lanschot JJB
    Dis Esophagus; 2017 Dec; 30(12):1-8. PubMed ID: 28881890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.
    van Rossum PSN; Goense L; Meziani J; Reitsma JB; Siersema PD; Vleggaar FP; van Vulpen M; Meijer GJ; Ruurda JP; van Hillegersberg R
    Gastrointest Endosc; 2016 May; 83(5):866-79. PubMed ID: 26632523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.
    Qin Q; Xu H; Liu J; Zhang C; Xu L; Di X; Zhang X; Sun X
    Int J Surg; 2018 Nov; 59():11-18. PubMed ID: 30261331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.
    van der Wilk BJ; Eyck BM; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Dig Surg; 2019; 36(6):462-469. PubMed ID: 30227434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged Time to Surgery in Patients with Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
    Overtoom HCG; Eyck BM; van der Wilk BJ; Noordman BJ; van der Sluis PC; Wijnhoven BPL; van Lanschot JJB; Lagarde SM;
    Ann Surg; 2024 Aug; ():. PubMed ID: 39140597
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.